-
Dr Shen on Adjuvant CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
20 May 2024 13:20 GMT
… )–positive, HER2-negative breast cancer.
The monarchE study evaluated … Kisqali) to a nonsteroidal aromatase inhibitor (NSAI) for the … HER2-negative early-stage breast cancer, Shen explains. This … of HR-positive breast cancer, where personalized treatment …
-
Truqap/Faslodex Delays Time to Breast Cancer Progression, Next Therapy
20 May 2024 13:17 GMT
… advanced or metastatic breast cancer. The trial included … advanced or metastatic breast cancer harboring one or … positive, HER2-negative breast cancer who experienced recurrence … aromatase inhibitor (AI), or during prior AI therapy for advanced breast cancer …
-
Ribociclib Plus NSAI Maintains Manageable Safety Profile in HR+/HER2– Early Breast Cancer
17 May 2024 21:51 GMT
… with a nonsteroidal aromatase inhibitor (NSAI) remained … , early-stage breast cancer, with most treatment … aromatase inhibitor (NSAID) in patients (pts) with HR+/HER2- early breast cancer … (EBC). Presented at: 2024 ESMO Breast Cancer …
-
Capivasertib/Fulvestrant Improves PFS2 in Pretreated PIK3CA/AKT1/PTEN+ HR+/HER2– Breast Cancer
16 May 2024 23:23 GMT
… advanced or metastatic breast cancer, including in … positive, HER2-negative breast cancer who experienced recurrence … with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer ( … capivasertib with fulvestrant for breast cancer. FDA. November …
-
Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer
16 May 2024 17:24 GMT
… ; palbociclib, 78%), an aromatase inhibitor (98%), fulvestrant (80%), … breast cancer, and the data shared at ESMO Breast Cancer … breast cancer research and executive chair of the Breast Cancer … factor negative advanced breast cancer (VERITAC-3). …
-
What Breast Cancer Means for Your Bones
16 May 2024 15:37 GMT
… to experience
another.”
And breast cancer survivors are even more … know about breast cancer and bone health:
How can breast cancer treatment … is skewed for breasties. Breast cancer treatments—chemotherapy, aromatase inhibitors, tamoxifen, ovarian surgery, …
-
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
20 May 2024 12:30 GMT
… to combined treatment with aromatase inhibitors and CDK4/6 … zotatifin in ER+ metastatic breast cancer and anticipate determination of … and abemaciclib in ER+ breast cancer. Efficacy data presented at … and abemaciclib in ER+ breast cancer and in Phase 2 …
-
Ribociclib succinate by Novartis for Pediatric Diffuse Intrinsic Pontine Glioma: Likelihood of Approval
17 May 2024 03:08 GMT
… combination with an aromatase inhibitor as initial endocrine- … negative advanced or metastatic breast cancer.
Ribociclib succinate is … , metastatic triple-negative breast cancer, peritoneal cancer, ALK … advanced or metastatic breast cancer in combination with …
-
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
16 May 2024 10:00 GMT
… breast cancer, and the data shared at ESMO Breast Cancer … Director Breast Cancer Research and Executive Chair, Breast Cancer Research … breast cancer in combination with an aromatase inhibitor as … common cancers, including breast cancer, genitourinary cancer, …
-
Celcuity Inc. (CELC) Q1 2024 Earnings Call Transcript
16 May 2024 01:16 GMT
… positive HER2-negative advanced breast cancer, whose disease progressed … 6 inhibitor and an aromatase inhibitor. And patients are … , especially in advanced breast cancer. The current second- … patients with advanced breast cancer are selective estrogen receptor …